What's Happening?
The Trump administration is appealing a Georgia court ruling that affects the Medicare Advantage star ratings for 2026. The ruling, which favored Clover Health, led to the removal of 20 measures used by
the Centers for Medicare & Medicaid Services (CMS) to calculate these scores. The court found that CMS exceeded its statutory authority in using certain data sources and failed to meet rulemaking requirements. This decision has prompted additional lawsuits from other insurers like Elevance Health and Alignment Healthcare, who are seeking recalculations of their scores. The appeal is seen as a strategic move by federal agencies to address these challenges and potentially influence other ongoing litigation.
Why It's Important?
The appeal has significant implications for the Medicare Advantage program, which ties quality bonus payments to star ratings. These payments have increased substantially, with estimates reaching $22 billion by 2026. Insurers like Elevance Health and Alignment Healthcare stand to gain millions in additional payments if the recalculations favor them. The case highlights ongoing debates about the effectiveness and fairness of the star rating system, with some experts suggesting a shift to a budget-neutral model. The outcome of the appeal could set a precedent for future litigation and impact how quality is measured in Medicare Advantage plans.
What's Next?
If the appeal is unsuccessful, further litigation is likely, as insurers may continue to challenge the star rating calculations. CMS must respond to the Elevance case by August 4, indicating a tight timeline for federal agencies. The decision could lead to broader reforms in the star rating system, potentially delinking scores from payments. Health plans not currently involved in lawsuits are closely monitoring the situation, which could influence their future actions. The appeal's outcome will be crucial in determining the direction of Medicare Advantage quality assessments.
Beyond the Headlines
The case raises questions about the transparency and accountability of the star rating system. Critics argue that the current measures may not accurately reflect improvements in plan quality, prompting calls for a reevaluation of the program's objectives. The litigation underscores the tension between regulatory authority and insurer interests, highlighting the complexities of healthcare policy. As the debate continues, stakeholders are considering the ethical implications of tying financial incentives to potentially flawed metrics.
